Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma
Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Primary:
Evaluate safety, feasibility, persistence, and anti-tumor effect of infused haploidentical
donor-derived natural killer (NK) cells and low-dose interleukin-2 (IL-2).
Secondary:
- Quantification of cytokine levels;
- Assessment of NK cell immunophenotype and function.